Overview

High Dose Steroid to Treat Flares in Inflammatory Bowel Disease

Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This study will examine whether delivery of high dose steroids directly into the bowel via its arterial blood supply will be better for treating and controlling flares of inflammatory bowel disease in patients compared to usual intra-venous or oral administration of this drug. Patients aged 4-25 years of age will be recruited. In this study, we hope to also learn how this directed steroid delivery will improve patient symptoms as well as the appearance of inflamed segments of bowel determined by imaging (i.e. an MRI scan) or biopsy (i.e. at the time of endoscopy). Additional data will determine how the blood vessels in the bowel affect, and drive, the mechanisms of inflammatory bowel disease.
Phase:
Phase 1
Details
Lead Sponsor:
Stanford University
Treatments:
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate